SCHEMBL4923650

SCHEMBL4923650

O=C(Nc1ccc(F)cc1)Nc1ccc(N2CCCCC2)c(F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.55
RAB9A P51151 6/20 0.55
MAPT P10636 5/20 0.55
KMT2A Q03164 4/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
GAA P10253 3/20 0.55
NPSR1 Q6W5P4 3/20 0.55
HTT P42858 2/20 0.55
KDM4E B2RXH2 2/20 0.55
ALDH1A1 P00352 2/20 0.55
MEN1 O00255 2/20 0.55
LMNA P02545 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.54
CNR1 P21554 1/20 0.53
TP53 P04637 1/20 0.52
ALOX15 P16050 1/20 0.52
MAPK1 P28482 1/20 0.52
POLB P06746 1/20 0.50
PKM P14618 1/20 0.49
HPGD P15428 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5176497 0.89 CNR1 (0.57) NPC1RAB9AMAPTKMT2ASMN1; SMN2
SCHEMBL4922838 0.89 CNR1 (0.57) NPC1RAB9AMAPTKMT2ASMN1; SMN2
SCHEMBL4920276 0.89 CNR1 (0.57) NPC1RAB9AMAPTKMT2ASMN1; SMN2
SCHEMBL4919660 0.88 CNR1 (0.59) NPC1RAB9AMAPTKMT2ASMN1; SMN2
SCHEMBL4917218 0.87 EPHX2 (0.57) NPC1RAB9AMAPTKMT2ASMN1; SMN2
SCHEMBL4924588 0.86 CNR1 (0.53) RAB9AMAPTKMT2AHTTKDM4E
SCHEMBL4920895 0.86 MEN1 (0.58) NPC1RAB9AMAPTKMT2ASMN1; SMN2
SCHEMBL4922756 0.86 RAB9A (0.53) NPC1RAB9AMAPTKMT2ASMN1; SMN2
SCHEMBL4924794 0.85 MAPT (0.50) NPC1RAB9AMAPTKMT2ASMN1; SMN2
SCHEMBL4920516 0.85 SLC2A1 (0.59) NPC1RAB9AMAPTKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP claimed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP disclosed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R NPC1 148/4885RAB9A 3359/4885MAPT 4151/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R NPC1 148/4885RAB9A 3359/4885MAPT 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.